Exelixis (EXEL) Curent Deferred Tax Liability (2011)

Exelixis (EXEL) recorded quarterly Curent Deferred Tax Liability of $700000.0 in Q4 2011.

Exelixis (EXEL) Curent Deferred Tax Liability (2011) Analysis & Trends

Exelixis' Curent Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $700000.0 for Q4 2011.

In Q4 2011, Curent Deferred Tax Liability changed N/A year-over-year to $700000.0; the TTM figure through Dec 2011 stood at $700000.0 (changed N/A YoY), while the FY2011 annual figure was $700000.0, changed N/A from the prior year.
Curent Deferred Tax Liability was $700000.0 for Q4 2011 at Exelixis.
In the past five years, Curent Deferred Tax Liability ranged from a high of $700000.0 in Q4 2011 to a low of $700000.0 in Q4 2011.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Curent Deferred Tax (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	-
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Exelixis	13.37 Bn	12.59 Bn	590.86 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2011	700,000.00
Dec 31, 2011	700,000.00